Back

Natera Inc

Ticker: NTRA ISIN: US6323071042
Add to portfolio Portfolio analysis in 2min
Stock Large-cap High beta Trading above 200-day average Near 52-week high
Market cap
$20.91B
Forward P/E
0.00
Profit margin
-14.01%
Revenue growth QoQ
63.90%
Beta
1.65
$332.03 2.21%
Price as of 2026-08-21 · NASDAQ

Performance by timeframe

Rolling returns
1 Month +28.68%
6 Months +58.60%
1 Year +104.36%
5 Years +23.60% p.a.+188.30%
10 Years +42.22% p.a.+3,277.72%
Since inception +27.22% p.a.+1,360.11%
Calendar year returns
YTD +44.93%
2025 +44.72%
2024 +152.71%
2023 +55.94%
2022 -56.99%
2021 -6.16%

Key stats

Market cap
20.91B
Beta
1.65
52-week range
75.19 - 183.00
50-day MA
168.08
200-day MA
132.74
Section 1

Business overview

Company profile data from fundamentals.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Sector Healthcare
Industry Diagnostics & Research
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -25.82%
ROA -9.96%
Profit margin -14.01%
Operating margin -8.94%
PEG ratio 0.00
Revenue/share TTM 12.59
Revenue TTM 1.53B
EBITDA -214.40M
Gross profit TTM 883.38M
Beta 1.65

Valuation

Trailing P/E 0.00
Forward P/E 0.00
P/B 24.36
P/S 13.65
EV/EBITDA -26.80
EV/Revenue 13.68
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -1.55
Quarterly earnings growth 0.00%
Revenue TTM 1.53B
Reported quarters 40
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0.00%
Last split date 0000-00-00
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price $171.93
Analyst rating 4.5556

Ownership & short interest

Shares outstanding 132.02M
Shares float 127.38M
Institutional ownership 95.51%
Insider ownership 4.32%
Short ratio 3.23
Short % of float 3.54%

Details

Instrument metadata and source update timestamps.

Symbol NTRA
Name Natera Inc
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US6323071042
Country USA
Code + exchange NTRA.NASDAQ
Fundamentals updated 2025-02-26

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.